ClinicalTrials.gg
CompletedNCT06865508Updated Mar 10, 2025

Photo Biomodulation Therapy for Alveolar Osteitis Recovery in Oral Contraceptive Users

An interventional study of Laser therapy and zinc oxide eugenol dressing. in Alveolar Osteitis, sponsored by Badr University. Completed at 1 site in Egypt. Open to female participants aged 25 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Badr University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Nov 2023, registered Mar 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
25 Years to 40 Years
Sex
Female
01

Study summary

does laser effect on alveolar osteitis recovery in oral contraceptive users ?

Read the detailed description

photo biomodulation therapy for alveolar osteitis recovery in oral contraceptive users

02

Conditions studied

  • Alveolar Osteitis

Browse trials for

Keywords

  • alveolar osteitis and oral contraceptive
03

In context

Dry Socket

46 studies on the registry are indexed under Dry Socket; 10 are open to participants now.

This study's enrollment of 50 is below the median of 60 across 41 interventional studies indexed under Dry Socket.

Browse Dry Socket studies →

Lead sponsor

Badr University is the lead sponsor of 64 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female patients aged 25-40 years. Currently using oral for at least 3 months prior to participation.

Diagnosed with dry socket (alveolar osteitis) based on clinical criteria.

Exclusion criteria

  • Exclusion Criteria:

Presence of systemic diseases (e.g., diabetes, immunodeficiency disorders). Smoking or tobacco use. Allergies to zinc oxide or other study materials. Use of antibiotics or anti-inflammatory medications within the last 2 weeks. Pregnancy or breastfeeding.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    1. Experimental Group: Laser therapy combined with zinc oxide eugenol dressing.

    * Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\]. * Zinc oxide eugenol dressing was applied immediately before the laser therapy. * The intervention will be performed at \[specified intervals every day 0, day7, day 14, day 30)\]

    Device: Laser therapy · Device: zinc oxide eugenol dressing.

  • Active comparator
    control group

    zinc oxide eugenol dressing.

    Device: zinc oxide eugenol dressing.

Interventions

  • DeviceLaser therapy

    Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].

  • Devicezinc oxide eugenol dressing.

    zinc oxide eugenol dressing.

06

What researchers measure

Primary outcomes

  1. pain intensity by VAS

    Pain intensity measured using a Visual Analog Scale (VAS) at day0, day7, day14 post-treatment.

    Time frame: 4 weeks

  2. Socket volume .

    measured using \[specific measurement technique, volumetric analysis\] at day0, day14 and 1-month post-treatment

    Time frame: 4 weeks

Secondary outcomes

  1. Quality of life assessed

    Quality of life assessed using the Oral Health Impact Profile (OHIP-5) questionnaire at day0, day7and day14 post-treatment.

    Time frame: 4 weeks

07

Study locations

1 site
  • physical therapy at Badr University in Cairo(BUC)
    Cairo, 11829, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Nov 2024, 12 months.

Of 22 interventional studies with no phase under Dry Socket, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 10, 2025
StartActual
Nov 1, 2023
Primary completionActual
Nov 1, 2024
CompletionActual
Dec 30, 2024
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06865508
Lead sponsor
Badr University
Responsible party
Doaa Saeed Mohamed (Lecturer, Badr University) — Principal investigator
First posted
Mar 10, 2025
Start date
Nov 1, 2023
Primary completion
Nov 1, 2024
Completion
Dec 30, 2024
Last update
Mar 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion